Johnson & Johnson (JNJ) said Wednesday that it has received approval from the US Food and Drug Administration for Imaavy, a treatment for generalized myasthenia gravis.
The treatment, also known as nipocalimab-aahu, has the potential to provide lasting disease control in adults and pediatric patients aged 12 and up who test positive for anti-acetylcholine receptor or anti-muscle-specific kinase antibody, the company said.
The company said applications for the approval of nipocalimab are being reviewed by regulatory authorities globally.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。